Abstract
Tumors are prothrombotic, while venous thromboembolic events are a leading cause of mortality in cancer patients. Venous thrombi resolve through a process of organization, including the formation of neovascular channels in the thrombus. Use of antiangiogenic therapy is associated with increased incidence and severity of venous thromboembolism. The aim was to investigate whether axitinib, a clinically used, selective vascular endothelial growth factor receptor inhibitor, affects resolution of venous thrombi.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of vascular surgery. Venous and lymphatic disorders
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
